Profiles of Coagulation and Fibrinolysis Activation-Associated Molecular Markers of Atypical Hemolytic Uremic Syndrome in the Acute Phase

Aim: Atypical hemolytic uremic syndrome (aHUS), characterized by thrombotic microangiopathy (TMA), is a genetic, life-threatening disease which needs many differential diagnoses. This study aimed to reveal coagulation and fibrinolysis profiles in aHUS and secondary TMA patients. Furthermore, we investigated whether aHUS patients progress to, and meet, disseminated intravascular coagulation (DIC) criteria. Methods: The acute phase samples were available in 15 aHUS and 20 secondary TMA patients. We measured PT-ratio, activated partial thromboplastin time (APTT), fibrinogen, fibrin degradation product (FDP), fibrin monomer complex (FMC), antithrombin (AT), plasmin-α2 plasmin inhibitor complex (PIC), and von Willebrand factor antigen (VWF:Ag). We examined and compared these tests among aHUS, secondary TMA patients, and healthy volunteer (HV), and evaluated whether patients with aHUS and secondary TMA met DIC criteria. Results: PT-ratio, APTT, FDP, FMC and PIC in patients with aHUS and secondary TMA were higher than those in HV. Fibrinogen and AT showed no significant difference among three groups. VWF:Ag was higher in only aHUS patients. No tests showed significant difference between aHUS and secondary TMA patients. Three aHUS patients out of 15 met DIC criteria. Conclusion: We revealed the profiles and distributions of coagulation and fibrinolysis tests of aHUS and secondary TMA patients. All tests were enhanced compared to HV; however, our results showed the no specificities in distinguishing aHUS from secondary TMA patients. We also clarified that some aHUS patients fulfilled DIC diagnostic criteria, indicating that DIC itself cannot be an exclusion criterion of aHUS.

[1]  M. Nangaku,et al.  Pathogenesis of Atypical Hemolytic Uremic Syndrome , 2019, Journal of atherosclerosis and thrombosis.

[2]  M. Nangaku,et al.  Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome , 2018, Clinical and Experimental Nephrology.

[3]  É. Azoulay,et al.  Expert Statements on the Standard of Care in Critically Ill Adult Patients With Atypical Hemolytic Uremic Syndrome , 2017, Chest.

[4]  T. Jokiranta.  HUS and atypical HUS. , 2017, Blood.

[5]  T. Cavero,et al.  Eculizumab in secondary atypical haemolytic uraemic syndrome , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  Y. Miyakawa,et al.  Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab , 2017, Medicine.

[7]  M. Noris,et al.  Disease : Improving Global Outcomes ” ( KDIGO ) Atypical hemolytic uremic syndrome and C 3 glomerulopathy : conclusions from a “ Kidney Controversies Conference , 2017 .

[8]  M. Nangaku,et al.  Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. , 2016, Clinical advances in hematology & oncology : H&O.

[9]  Kohji Okamoto,et al.  Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis , 2016, Thrombosis Journal.

[10]  [Clinical Guides for Atypical Hemolytic Uremic Syndrome in Japan]. , 2016, Nihon Jinzo Gakkai shi.

[11]  P. Zipfel,et al.  Atypical aHUS: State of the art. , 2015, Molecular immunology.

[12]  E. Conway,et al.  Reincarnation of ancient links between coagulation and complement , 2015, Journal of thrombosis and haemostasis : JTH.

[13]  C. Bedrosian,et al.  Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. , 2015, Blood.

[14]  S. Kurosawa,et al.  Complement, thrombotic microangiopathy and disseminated intravascular coagulation , 2014, Journal of Intensive Care.

[15]  Tao Zhang,et al.  A Non-Invasive Laboratory Panel as a Diagnostic and Prognostic Biomarker for Thrombotic Microangiopathy: Development and Application in a Chinese Cohort Study , 2014, PloS one.

[16]  J. George,et al.  Syndromes of thrombotic microangiopathy. , 2014, The New England journal of medicine.

[17]  V. Michael Holers,et al.  Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. , 2014, Blood.

[18]  G. Lippi,et al.  Influence of centrifuge brake on residual platelet count and routine coagulation tests in citrated plasma , 2014, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[19]  S. Kushimoto,et al.  Increased Ratio of Soluble Fibrin Formation/Thrombin Generation in Patients With DIC , 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[20]  T. Nobori,et al.  Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases. , 2012, Thrombosis research.

[21]  D. Ricklin,et al.  Interactions between coagulation and complement—their role in inflammation , 2011, Seminars in Immunopathology.

[22]  P. Théroux,et al.  Requirements for Membrane Attack Complex Formation and Anaphylatoxins Binding to Collagen-Activated Platelets , 2011, PloS one.

[23]  John D Lambris,et al.  Molecular Intercommunication between the Complement and Coagulation Systems , 2010, The Journal of Immunology.

[24]  G. Remuzzi,et al.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[25]  B. Nilsson,et al.  Complement and coagulation: strangers or partners in crime? , 2007, Trends in immunology.

[26]  Hiroyuki Ebinuma,et al.  The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products. , 2007, Thrombosis research.

[27]  A. Sudo,et al.  Elevated levels of soluble fibrin or D‐dimer indicate high risk of thrombosis , 2006, Journal of thrombosis and haemostasis : JTH.

[28]  W. Fridman,et al.  Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. , 2005, Journal of the American Society of Nephrology : JASN.

[29]  S. D. Subba Rao,et al.  Atypical hemolytic uremic syndrome. , 2002, Indian pediatrics.

[30]  F B Taylor,et al.  Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation , 2001, Thrombosis and Haemostasis.

[31]  E. de Jonge,et al.  [Disseminated intravascular coagulation]. , 1977, Nederlands tijdschrift voor geneeskunde.

[32]  G. Remuzzi,et al.  Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. , 1999, Journal of the American Society of Nephrology : JASN.

[33]  J. Goodship,et al.  Genetic studies into inherited and sporadic hemolytic uremic syndrome. , 1998, Kidney international.

[34]  A. Mantovani,et al.  The Cytolytically Inactive Terminal Complement Complex Activates Endothelial Cells to Express Adhesion Molecules and Tissue Factor Procoagulant Activity , 1997, The Journal of experimental medicine.

[35]  T. Horiuchi,et al.  C5a Induces Tissue Factor Activity on Endothelial Cells , 1997, Thrombosis and Haemostasis.

[36]  岡本 好司.  Coagulopathy in disseminated intravascular coagulation due to abdominal sepsis : determination of prothrombin fragment 1+2 and other markers , 1992 .

[37]  J. Moake,et al.  Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. , 1986, The Journal of clinical investigation.

[38]  P. Sims,et al.  Effect of complement proteins C5b-9 on blood platelets. Evidence for reversible depolarization of membrane potential. , 1985, The Journal of biological chemistry.

[39]  M. Polley,et al.  Human platelet activation by C3a and C3a des-arg , 1983, The Journal of experimental medicine.

[40]  T Maekawa,et al.  Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. , 1983, Bibliotheca haematologica.